## NEW FELLOWS 2022



Australian Academy of Health and Medical Sciences

### Welcome from the President

On behalf of the Council and Fellowship of the Australian Academy of Health and Medical Sciences, I am delighted to warmly welcome this year's newly elected Fellows to the Academy.

Academy Fellowship is granted in recognition of outstanding leadership and significant and continuing contributions to health and medical sciences in Australia. The diversity and depth of talent among the new Fellows elected each year is testimony to the exceptional contributions that Australian clinician researchers and scientists make to global efforts to prevent and manage disease, and to improve the health of the society.

As a Fellowship, we advance health and medical research in Australia and its translation into benefits for all, by fostering leadership within our sector, providing expert advice to decision makers, and engaging patients and the public. I trust our new Fellows will embrace the activities of the Academy and I look forward to seeing the ways in which they bring their expertise to help the Academy to achieve these goals.

Arguid Scheffer

Professor Ingrid Scheffer AO FRS FAA PresAHMS President



Australian Academy of Health and Medical Sciences

The Australian Academy of Health and Medical Sciences is the impartial, authoritative, cross-sector voice of health and medical science in Australia. We advance health and medical research in Australia and its translation into benefits for all, by fostering leadership within our sector, providing expert advice to decision makers, and engaging patients and the public.

We are an independent, interdisciplinary body of Fellows – elected by their peers for their outstanding achievements and exceptional contributions to health and medical science in Australia. Collectively, they are a representative and independent voice, through which we engage with the community, industry and governments.

The Academy is uniquely positioned to convene cross-sector stakeholders from across Australia to address the most pressing health challenges facing society. We focus on the development of future generations of health and medical researchers, on providing independent advice to government, and on providing a forum for discussion on progress in health and medical research with an emphasis on translation of research into practice.

The Academy is registered with the Australian Charities and Not-for-profits Commission (ACNC) and is endorsed as a deductible gift recipient.

ABN: 55 167 124 067

#### www.aahms.org



### Table of Contents

Professor David Burgner	2
Professor Leonid Churilov	2
Professor Jennifer Couper	3
Professor Phillip Darcy	3
Professor Ian Davis	4
Professor Denise Doolan	4
Professor Dominic Dwyer	5
Professor Peter Ebeling	5
Professor Aleksandra Filipovska	6
Professor Susan Fletcher	6
Professor Ian Freckelton	7
Professor Michael Friedlander	7
Professor Sharon Friel	8
Professor Sarah Hilmer	8
Professor Jane Hocking	9
Professor Carol Hodgson	9
Professor Anne Kavanagh	10
Professor Emma Kowal	10
Professor Kristine Macartney	11
Professor Laura Mackay	11
Professor Eric Morand	12
Professor Anna Nowak	12
Professor Shanthakumar Rajaratnam	13
Professor Jason Roberts	13
Professor Ben Solomon	14
Professor Mark Stevenson	14
Dr Norman Swan	15
Professor Bruce Taylor	15
Distinguished Professor Patsy Yates	16
Professor Di Yu	16
Professor Sophia Zoungas	17

# O R D I N A R Y F E L L O W S



### Professor David Burgner

#### Honours and Recognition: FAHMS

Primary Position: Senior Research Fellow and Group Leader Institute: Murdoch Children's Research Institute State: Victoria

Professor David Burgner is a practising paediatric infectious diseases physician, leads the Inflammatory

Origins Group and co-leads the LifeCourse longitudinal observational cohorts initiative at Murdoch Children's Research Institute. He is Education Officer for the World Society of Paediatric Infectious Diseases.

Professor Burgner is an international authority on understanding the susceptibility and consequences to childhood infection and inflammation, particularly in relation to the development of cardiometabolic disease risk. He is an internationallyrecognised clinical and scientific leader in Kawasaki disease and has made major scientific, clinical and policy contributions to the Australian response to the COVID-19 pandemic, particularly the hyperinflammatory post-infectious syndrome in children.

### Professor Leonid Churilov

#### Honours and Recognition: FAHMS Primary Position: Professor In Biostatistics Institute: The University of Melbourne State: Victoria



Professor Leonid Churilov is a clinical biostatistician who led complex and comprehensive design and analysis of

acute and recovery stroke trials that resulted in global changes in clinical practice, and are internationally recognised through multiple publications in the highest impact medical journals including *NEJM*, *The Lancet* and *JAMA*.

Professor Churilov led the development, and wide adoption by the Australian stroke clinical community, of novel clinical trial designs, original analytical approaches and outcome measurements from "bench-to-bedside". His decisionmodelling effort provided analytical underpinnings for acute stroke processes of care adopted both nationally and internationally, including the activities of the first Australian stroke ambulance.



#### Professor Jennifer Couper

Honours and Recognition: FAHMS Primary Position: Head of Paediatrics Institute: The University of Adelaide State: South Australia

Professor Jenny Couper is a practising clinician and researcher who leads innovations for children at-risk or

with type 1 diabetes. Her research is in the prevention of type 1 diabetes and the prevention of cardiovascular complications. She heads the first global investigation of the early life origins of type 1 diabetes and co-leads prevention trials. Through her work, she has found ways to detect cardiovascular disease early in children with type 1 diabetes and shown the benefits of exercise, diet and medication.

Professor Couper trains paediatric endocrinologists, writes international guidelines and facilitates international training on the International Society of Pediatrics and Adolescent Diabetes Advisory Council.

#### **Professor Phillip Darcy**

#### Honours and Recognition: FAHMS

Primary Position: Group Leader, Cancer Immunotherapy Laboratory

Institute: Peter MacCallum Cancer Centre

#### State: Victoria

Professor Phillip Darcy is an NHMRC Principal Research



Fellow and Group Leader at the Peter MacCallum Cancer Centre. His work has been pivotal in developing novel T cell-based immunotherapy approaches for cancer patients. In particular, his studies involving the development of technology using gene-modified T cells expressing chimeric antigen receptors (CARs) in preclinical models has led to licensing of an international patent to industry partners and underpins five FDA/TGA-approved therapies for CD19+ blood cancers.

Professor Darcy's work has also been integral in the first CAR T cell trial undertaken in Australia.



### **Professor Ian Davis**

Honours and Recognition: FAHMS Primary Position: Professor of Medicine; Head, Eastern Health Clinical School Institute: Monash University State: Victoria

Professor Ian Davis is a medical oncologist with over 30 years' experience and primary clinical and research focus in genitourinary cancers. He founded and chairs the ANZUP (Australian and New Zealand Urogenital and Prostate) Cancer Trials Group and is the global co-chair of international ANZUP ENZAMET trial. This trial demonstrated improved survival with enzalutamide for metastatic hormonesensitive prostate cancer and has led to regulatory approval in US, Europe, Japan, and Australia, leading to multiple awards, including the 2020 Trial of the Year.

Through ANZUP, Professor Davis has established a global genitourinary cancer clinical trials network and mentored many senior clinician-researchers.

### Professor Denise Doolan

#### Honours and Recognition: FAHMS

Primary Position: Professorial Research Fellow of Infectious Diseases Immunology

Institute: James Cook University

#### State: Queensland



Professor Denise Doolan is a Professorial Research Fellow and Acting Director of the Australian Institute of Tropical Health and Medicine at James Cook University. She is a molecular immunologist with multidisciplinary research focuses on developing therapeutics and diagnostics for infectious diseases that impact global public health.

Professor Doolan's research has provided critical insights into multiple facets of malaria immunology, vaccine antigens, and vaccine and diagnostic platform development, extending to the more general fields of immunology, vaccinology and public health. Professor Doolan champions health and medical research and capacity development for populations in the tropics, including regional Australia.



### Professor Dominic Dwyer

Honours and Recognition: FAHMS Primary Position: Director, Institute of Clinical Pathology and Medical Research (ICPMR); Director of Public Health Pathology, NSW Health Pathology

Institute: Westmead Hospital State: New South Wales

Professor Dominic Dwyer is a clinical virologist and infectious diseases physician, trained in Sydney with doctoral research undertaken at the Institut Pasteur, Paris. He is the NSW Director of Public Health Pathology, and Director of the Institute Of Clinical Pathology and Medical Research (ICPMR) at Westmead. He is an expert in emerging infections, an investigator in many antiviral drug/vaccine trials, and has published over 480 papers. He has worked with the World Health Organization, including as a member of the WHO Study of the Origins of SARS-CoV-2 (Wuhan 2021).

Professor Dwyer has a prominent media presence, and has worked on various international and national committees and advisory boards.

### **Professor Peter Ebeling**

#### Honours and Recognition: AO FAHMS

Primary Position: Head, Department of Medicine

Institute: Monash University

#### State: Victoria

Professor Peter Ebeling's national and international recognition for excellence in health and medical science

is demonstrated by key leadership roles at the highest level, including as first non-North American President of the American Society of Bone and Mineral Research, Past-president of the Endocrine Society of Australia and Australian and New Zealand Bone and Mineral Society, and Board Member of the International Osteoporosis Foundation. Professor Ebeling mentors PhD students and endocrinology trainees and chairs Healthy Bones Australia, through which he has raised public understanding of bone health.

Professor Ebeling's significant, sustained and ongoing contributions to advance health and medical science have led to changes in clinical practice and health policy.



### Professor Aleksandra Filipovska

Honours and Recognition: FAHMS

**Primary Position:** Professor and NHMRC Senior Research Fellow; Deputy Director, ARC Centre of Excellence in Synthetic Biology (COESB)

Institute: The University of Western Australia

State: Western Australia

Professor Aleksandra Filipovska is internationally renowned for her pioneering work in mitochondrial genomics and disease. She is Deputy Director of the ARC Centre for Synthetic Biology and NHMRC Senior Research Fellow at the University of Western Australia. As co-director at the Mito Foundation, Professor Filipovska plays a key role in advocating for the mitochondrial disease community and mitochondrial donation.

Professor Filipovska has developed new technologies that have re-defined the mitochondrial transcriptome, its regulation, and diagnosis of patients with mitochondrial and metabolic diseases. She has licensed her genome-editing technology, which is currently used for clinical trials of neurodegenerative diseases internationally.

### Professor Susan Fletcher

Honours and Recognition: AO FAHMS Primary Position: Chief Scientific Officer Institute: PYC Therapeutics Ltd State: Western Australia



Professor Susan Fletcher is Senior Principal Research Fellow at Murdoch University and in 2020 was appointed

Chief Scientific Officer (fractional position) at ASX-listed biotech PYC Therapeutics. Alongside her collaborator Professor Steve Wilton, she pioneered 'molecular drugs' to treat inherited disease by altering the gene message to overcome diseasecausing mutations. In 2016, 2019 and 2021, the drugs ExonDys51, Vyondys53 and Amondys45 (respectively) from their laboratory became the first and only drugs to have altered the natural history of the fatal inherited muscle disease, Duchenne muscular dystrophy.

As lead investigator, Professor Fletcher is working with PYC Therapeutics to take VP-001 through clinical development to treat retinitis pigmentosa 11.



#### **Professor Ian Freckelton**

Honours and Recognition: AO FASSA FAHMS Primary Position: Professor of Law Institute: The University of Melbourne State: Victoria

Professor Ian Freckelton, King's Counsel, has made extensive contributions to health law and policy through

his roles as an academic, researcher and teacher and through his involvement in national committees. His extraordinary contributions to heath law have been both considerable and influential, particularly as the founder of the *Journal of Law and Medicine*, which attracts international recognition, citations and submissions.

Professor Freckelton has made further outstanding contributions through collaborative publishing, particularly through his series of edited books, including *Controversies in Health Law Disputes and Dilemmas in Health Law* and *Tensions and Traumas in Health Law*.

#### Professor Michael Friedlander

#### Honours and Recognition: AM FAHMS

Primary Position: Senior Staff Specialist in Medical Oncology Institute: Prince of Wales Hospital

#### State: New South Wales

Professor Michael Friedlander has an extensive track record of research into gynaecological and breast



malignancies, with major focus on innovative clinical trials in ovarian cancer and using patient reported outcomes as endpoints in clinical trials. His extensively cited and influential work has led to important, lasting changes in clinical cancer treatment and improved patient outcomes.

Professor Friedlander is recognised both nationally and internationally and has a long-term track record of effective leadership, training and mentorship in the discipline.



### **Professor Sharon Friel**

Honours and Recognition: FASSA FAHMS Primary Position: Professor of Health Equity Institute: Australian National University State: Australian Capital Territory Professor Sharon Friel is a world-renowned policyfocused health equity researcher. She is an ARC Laureate

Fellow since 2021 and Director of Menzies Centre for Health Governance, Australian National University. Professor Friel was Head of the Scientific Secretariat (University College London) for the World Health Organisation Commission on Social Determinants of Health. She has published widely on the social and environmental determinants of health equity, with more than 200 scholarly outputs and an h-index of 64 (Google Scholar).

In 2014, Professor Friel was voted into the top 100 female global health leaders and in 2015 she was elected Fellow of the Academy of Social Sciences Australia.

### Professor Sarah Hilmer

#### Honours and Recognition: AM FAHMS

Primary Position: Head of Department of Clinical Pharmacology and Senior Staff Specialist in Aged Care

Institute: Royal North Shore Hospital/The University of Sydney State: New South Wales



Professor Sarahn Hilmer is nationally and internationally recognised for excellence in geriatric pharmacology. She has made significant, sustained contributions to the field since her PhD was awarded in 2005, with over 300 publications and 10,000 citations, and national and international collaborations. She has chaired institutional, state and international committees aiming to advance clinical pharmacology and therapeutics, particularly for older adults. She performs editorial responsibilities for gerontology and clinical pharmacology journals.

Professor Hilmer has built capacity in the emerging field of geriatric pharmacology through supervision of multidisciplinary higher degree students and mentorship of national and international early career clinician scientists. She actively engages with clinicians, policy makers and consumers to promote geriatric pharmacology research and practice.



### **Professor Jane Hocking**

Honours and Recognition: FAHMS Primary Position: Head, Sexual Health Unit Institute: The University of Melbourne State: Victoria

Professor Jane Hocking is an epidemiologist, whose research on chlamydia has led to paradigm changes in

policy, with changed treatment guidelines globally. She has demonstrated excellence through multiple plenary and symposia presentations at international conferences and membership on national and international committees informing policy. She has published over 375 peer-reviewed papers, with publications in *NEJM* and *The Lancet*, and has attracted \$57 million in funding.

Professor Hocking has made sustained contributions to the profession through journal editorial roles, conference organising and peer-review, and received prestigious awards for research excellence. She has promoted health and medical science in the community and enhanced primary-care workforce capacity through education, training and resources.

### Professor Carol Hodgson

#### Honours and Recognition: FAHMS

**Primary Position:** Head of the Division of Clinical Trials and Cohort Studies; Deputy Director, ANZIC-RC



Institute: Monash University

#### State: Victoria

Professor Carol Hodgson has an exceptional track record and leads a multidisciplinary, international research program in functional recovery after critical illness. This program has changed clinical practice and contributed new knowledge in the field, including international guidelines. Professor Hodgson is ranked in the top 1% worldwide for her expertise in topics such as 'Critical Care', 'ECMO' and 'Clinical Trials', and has been ranked number one globally for 'Early Ambulation' (https://expertscape.com/).

At Monash University, Professor Hodgson leads the Division of Clinical Trials, the NHMRC Centre for Research Excellence in ICUs, the National NHMRC-funded ECMO Registry and multiple international clinical trials. She is also an ICU Specialist Physiotherapist at The Alfred Hospital.



### Professor Anne Kavanagh

Honours and Recognition: FASSA FAHMS Primary Position: Professor of Disability and Health Institute: The University of Melbourne State: Victoria

Professor Anne Kavanagh is an epidemiologist and public health physician who has made substantial

contributions to knowledge across three areas: cancer screening, health inequities and disability. Her research has had major impacts on policy, including in relation to mammographic screening, local government priorities to promote healthy behaviour and approaches to improving the health of people with disability through reducing disability-related discrimination and violence, as well as improving employment outcomes for people with disability and ensuring people with disability have been safe during COVID-19.

In addition to her over 300 publications, Professor Kavanagh writes for online media and is a regular commentator in mainstream media.

#### Professor Emma Kowal

Honours and Recognition: FASSA FAHMS Primary Position: Professor of Anthropology Institute: Deakin University

#### State: Victoria

Professor Emma Kowal is a leading expert in the social,

ethical and cultural implications of genomics in Aboriginal

and Torres Strait Islander communities. As a result of her research, Indigenous genomics has developed as a recognised area of importance both within Indigenous health and within precision medicine.

Professor Kowal's work developing national frameworks for biospecimen handling and a training program for Indigenous people in genomics has been recognised internationally. Her contributions, particularly through the National Centre for Indigenous Genomics, the Genomics Health Futures Mission and Genomics Australia will allow Indigenous Australians to access the benefits of genomics and precision medicine.





### **Professor Kristine Macartney**

Honours and Recognition: FAHMS Primary Position: Director Institute: National Centre for Immunisation Research and Surveillance (NCIRS) State: New South Wales

Professor Kristine Macartney is a vaccinologist, infectious diseases paediatrician and Director of the National Centre for Immunisation Research and Surveillance (NCIRS). She is an expert on vaccine safety, policy and implementation, and vaccine preventable viral diseases, including influenza, SARS-CoV-2 (cause of COVID-19), rotavirus and varicella-zoster. Professor Macartney is a member of WHO advisory groups, including the Global Advisory Committee on Vaccine Safety and COVID-19 in Education and serves all key vaccine/communicable disease Australian advisory committees. Alongside over 200 publications, she is also Senior Editor of *The Australian Immunisation Handbook*.

Professor Macartney leads networked expert assistance on routine and COVID-19 vaccine delivery to multiple Indo-Pacific countries.

#### Professor Laura Mackay

Honours and Recognition: FAHMS Primary Position: Professor and Laboratory Head Institute: The Doherty Institute State: Victoria



Professor Laura Mackay is a Howard Hughes and Bill and Melinda Gates-funded International Scholar, Sylvia and

Charles Viertel Senior Research Fellow, NHMRC Leadership Fellow and Dame Kate Campbell Fellow. She has is an internationally recognised expert in T cell immunity, contributing landmark papers that have defined how memory T cell responses are generated in body tissues (Science, Nature, Nature Immunol, Nature Medicine, Immunity).

Professor Mackay's work has been recognized by prestigious fellowships, international grant funding, speaking invitations and Awards including The Gottschalk Medal (AAS) and Prime Minister's Prize for Frank Fenner Life Scientist of the Year.



### **Professor Eric Morand**

Honours and Recognition: FAHMS Primary Position: Head, School of Clinical Sciences Institute: Monash University State: Victoria

Professor Eric Morand is an internationally renowned academic physician-scientist. His career has focused on

integrating clinical and laboratory science to advance patient outcomes in lupus.

Professor Morand founded a multinational consortium to design and validate new clinical endpoints, solving a decade-long impasse responsible for multiple failed trials. He led the breakthrough Phase 3 trial of the novel medicine anifrolumab, resulting in approval of only the second new medicine for lupus in 60 years and formally validating a key aspect of SLE pathogenesis. Professor Morand's work identifying molecular targets for an alternative to steroids won the highest award of the Lupus Research Alliance, US.

#### Professor Anna Nowak

#### Honours and Recognition: FAHMS

**Primary Position:** Pro Vice Chancellor (Health and Medical Research)

Institute: The University of Western Australia

#### State: Western Australia

Professor Anna Nowak is a medical oncologist,



clinical triallist and tumour immunology researcher with a focus on the cancer mesothelioma. She developed the first measurement criteria specific to the unique growth pattern of mesothelioma, which are used in clinical trials worldwide. Professor Nowak was an early investigator of chemo-immunotherapy combinations in the laboratory, advancing our understanding of synergy between these treatments. She has subsequently progressed this work to a number of human clinical trials of chemo-immunotherapy, with a recent efficacious combination progressing through to an international randomised clinical trial.

Professor Nowak is currently Pro Vice Chancellor (Health and Medical Research) at UWA.



### Professor Shanthakumar Rajaratnam

Honours and Recognition: FAHMS Primary Position: Academic Head, School of Psychological Sciences; Deputy Director, Turner Institute for Brain and Mental Health

Institute: Monash University

State: Victoria

Professor Shantha Rajaratnam's research has taken circadian neuroscience into new clinical approaches: melatonin agonist (to FDA approval), light therapy and digital applications. He has published more than 165 peer-reviewed papers and two edited books, and he has led the peak body for sleep health and medicine (Australasian Sleep Association). He currently leads the Sleep Health Foundation.

Professor Rajaratnam was a Program Leader for the Alertness CRC (>\$90 million), and a Chief Investigator on two NHMRC Centres for Research Excellence. At Monash, he established a multi-disciplinary sleep research program (now with nine labs), and a sleep research network across the university and six affiliated hospitals.

### Professor Jason Roberts

Honours and Recognition: FAHMS Primary Position: Professor, School of Pharmacy Institute: The University of Queensland State: Queensland

Professor Jason Roberts has been instrumental in guiding evidence-based dosing of antimicrobials in critically ill



patients with serious infections. This work has been recognised internationally for its global impact and he is the most published author in this field worldwide, as his findings form the basis of numerous therapeutic guidelines.

Professor Roberts has a substantial record in mentoring both pharmacists and physicians in research methods, with trainees coming to Australia from many parts of the world specifically to be guided by him.



### Professor Ben Solomon

Honours and Recognition: FAHMS Primary Position: Consultant Medical Oncologist Institute: Peter MacCallum Cancer Centre State: Victoria

Professor Ben Solomon is a clinician-scientist whose clinical and translational research has identified new

treatments, changed standards of care and improved outcomes for patients with lung cancer, the leading cause of cancer-related death. His work has resulted in regulatory approvals for first, second and third generation ALK TKIs, defining new and transformative standards of care in this population.

Professor Solomon's ongoing leadership role in global clinical trials and as scientific chair and founding board member of the Thoracic Oncology Group of Australasia will ensure conduct and implementation of research that improves outcomes for lung cancer patients in Australia and worldwide.

#### Professor Mark Stevenson

#### Honours and Recognition: FAHMS

Primary Position: Professor of Urban Transport and Public Health

Institute: The University of Melbourne

#### State: Victoria



Professor Mark Stevenson is an internationally renowned epidemiologist whose research and advocacy have led to transport and public health policies that have reduced the global burden of injury. His landmark research associated with mobile phone use and the risk of car crash led to legislative change across five countries. Additionally, his research on young driver crashes has influenced licensing policies in Australia and his research on toddler drownings has led to legislation requiring four-sided isolation pool fencing.

Professor Stevenson's leadership and mentorship have been recognised, internationally, and his ability to deliver injury prevention interventions into mainstream systems, highlight the enormous utility of his work.



#### Dr Norman Swan

Honours and Recognition: FAHMS Primary Position: Broadcaster and Journalist, Science and Health

Institute: Australian Broadcasting Corporation State: New South Wales

Dr Norman Swan has been Australia's top health and medical science broadcaster for the last four decades, producing and delivering radio and TV programs across all areas. He is nationally and internationally recognised as an outstanding communicator to educate the public about the latest research in health, disease, treatments and research.

Dr Swan has championed good and criticised bad or unethical research, interviewed researchers and consumers globally, translating the information to improve health literacy and evidence-based choices. During the COVID-19 pandemic, Dr Swan has become an important face and voice of reason for many.

### **Professor Bruce Taylor**

Honours and Recognition: FAHMS

Primary Position: Professorial Research Fellow

Institute: Menzies Institute for Medical Research

State: Tasmania

Professor Bruce Taylor is a clinician-scientist who leads a large and diverse research group, undertaking



internationally significant research in the field of neuroscience. He is also a senior consultant neurologist with a special interest in multiple sclerosis (MS).

Professor Taylor's research focuses on the personal, environmental and genetic factors associated with the onset and progression of MS. This work has resulted in significant breakthroughs in our understanding of the aetiology of MS and the factors associated with the highly variable progression of MS. Through his work, Professor Taylor has made significant contributions into the understanding of the role of the environment in MS onset and progression.



### Distinguished Professor Patsy Yates

Honours and Recognition: AM FAHMS Primary Position: Executive Dean, Faculty of Health Institute: Queensland University of Technology State: Queensland

Distinguished Professor Patsy Yates is over 20 years post-PhD and is a leading authority in palliative care services

research. She has significant original contributions that have had a positive impact on health and medical research, the health system, economy and/or the health of the population, particularly in cancer and palliative care services.

Distinguished Professor Yates has led major independent programs involving national and international collaborative networks and she has an extensive mentoring and leadership portfolio. She is currently Executive Dean (Faculty of Health) at Queensland University of Technology, Centre Director for the Centre for Healthcare Transformation, and Director of the Centre for Palliative Care Research and Education, Queensland Health.

### Professor Di Yu

#### Honours and Recognition: FAHMS

**Primary Position:** Professor of Immunology, Group Leader **Institute:** The University of Queensland

#### State: Queensland



Professor Di Yu is an immunologist, global highly cited researcher, and NHMRC Leadership Fellow. He is

internationally recognised for the discovery of novel T lymphocyte subsets and their molecular regulators, relevant to health and disease. Bridging the gap between basic immunology and translation, Professor Yu actively collaborates with clinicians and has initiated clinical studies and trials for immune-related disease and immunisation. One such example is the investigator-driven trials of low-dose interleukin-2 therapy in lupus, which have altered clinical practice.

Professor Yu achievements in basic research and translation have been recognised by several awards, including the Academy's Jian Zhou Medal.



#### Professor Sophia Zoungas

Honours and Recognition: FAHMS Primary Position: Head, School of Public Health and Preventive Medicine Institute: Monash University State: Victoria

Professor Sophia Zoungas, Head of the School of Public Health and Preventive Medicine at Monash University, is a Clinical Endocrinologist recognised internationally for her role in advancing knowledge in the management of diabetes and its vascular complications. She leads Australia's largest translational research program in diabetes care and benchmarking of diabetes services.

Professor Zounga's research has led to improved prescribing for control of glucose and other cardiovascular risk factors among people with diabetes and identified new models of care that promote equity of access to best practice in the Australian community.

Australian Academy of Health and Medical Sciences

PO Box 6114, Woolloongabba, QLD 4102 Gabba Towers, 411 Vulture Street, Woolloongabba, QLD 4102 www.aahms.org | info@aahms.org +61 (0) 7 3102 7220